Cellex Celebrates 25 Years with Experts at the Cellex Symposium 2026
On November 8, 2026, the Cellex Symposium 2026 took place at the stunning Wasserturm Hotel in Cologne, Germany. This prestigious event gathered over 100 prominent researchers, clinicians, and industry leaders to discuss cutting-edge advancements in the field of cell and gene therapy. The theme for this year's symposium, "Cell and Gene Therapy at a Turning Point," aptly reflected the critical milestones reached in this rapidly evolving sector.
As Cellex marks its 25th anniversary, the symposium not only celebrated its rich history but also illustrated its evolution from a service provider for stem cell donor registries into a fully-fledged cell therapy contract development and manufacturing organization (CDMO). The commitment of Cellex to innovation and quality in cell therapies has made significant strides, now influencing both local and global markets.
The symposium was structured into three distinct scientific sessions, each addressing various aspects of research and application in cell and gene therapy. The opening session, titled "Translation From Cells to Clinical Impact," focused on transitioning cellular therapies into clinical settings. Esteemed speakers, including Dr. Hyatt Balke-Want from University Hospital Cologne and Matthias Domogalla from Cellex, highlighted advancements like genome-engineered T cells, allogeneic immune-cell therapies in treating sepsis, and the critical role of Good Manufacturing Practices (GMP) compliance in boosting manufacturing performance.
The second session, themed "Targeting," delved into therapies aimed at tackling hard-to-treat cancers and genetic disorders. Presentations from renowned professionals such as Prof. Elke Jäger from North-West Hospital Frankfurt and Dr. Ali Mohammed from Immatics Biotechnologies discussed innovative approaches, including peptide vaccines, gene editing platforms, and targeted therapies for solid tumors and hematologic malignancies. This session emphasized the importance of tailored therapies to improve patient outcomes.
In an interactive segment, guided expert tables provided an avenue for discussions on the role of artificial intelligence in regulated environments and ensuring product quality across various manufacturing sites. This discussion revealed a shared commitment among participants to fostering innovation while adhering to regulatory guidelines.
The closing session, "Market Reality," focused on scaling production in the biotech industry. Speakers including Rachel Atlee from Akron Bio and Dr. Suvi Annala from Cellex discussed the importance of raw materials and integrated CDMO models, as well as the growing influence of China in the global biotech landscape.
Professor Dr. Martin Wermke, Director of the Early Clinical Trial Unit at the National Center for Tumor Diseases Dresden, remarked on the symposium's value as an opportunity for reconnecting with peers and shaping discussions that will impact the next decade in cell and gene therapy. This sentiment echoed Dr. Armin Ehninger, Chief Scientific and Strategic Officer at Cellex, who emphasized the necessity of synchronizing scientific, manufacturing, and regulatory expertise to ensure that advanced therapies reach patients effectively.
In summary, the Cellex Symposium 2026 served as a pivotal platform for knowledge exchange, celebrating 25 years of Cellex's dedication to enhancing the field of cell and gene therapy. As the industry continues to evolve, the collaborative spirit fostered at this symposium is set to steer future innovations and improve patient care worldwide. For more on Cellex and its milestones, visit
Cellex's website.